---
title: "TAKEDA DEVELOPMENT CENTRE EUROPE LTD. - Payment Practices"
date: 2019-10-03
url: https://paymentcheck.co.uk/company-search/03638034/takeda-development-centre-europe-ltd
description: "View payment practices for TAKEDA DEVELOPMENT CENTRE EUROPE LTD.. Average time to pay: 32 days."
---

# TAKEDA DEVELOPMENT CENTRE EUROPE LTD.

## Company Information

- **Company Number:** 03638034
- **Status:** Active
- **Company Type:** Private limited Company
- **Incorporated:** 21 September 1998
- **Registered Address:** 1 Kingdom Street, London, England, W2 6BD
- **Industry:** Professional Services
- **Region:** London

## Payment Statistics

- **Average Time to Pay:** 32 days
- **Invoices Paid Within 30 Days:** 68%
- **Invoices Paid Between 31-60 Days:** 11%
- **Invoices Paid Later Than 60 Days:** 21%
- **Invoices Not Paid Within Agreed Terms:** 7%

## Payment Terms

- **Standard Payment Terms:** The majority of suppliers are subject to local standard terms of purchase or qualify as small medium businesses and are subject to standard payment terms of 30 or 45 days from receipt of a valid invoice. Global and larger local suppliers with negotiated contracts are subject to standard payment terms of up to 90 days from receipt of a valid invoice
- **Shortest Payment Period:** 30 days
- **Longest Payment Period:** 90 days
- **Maximum Contractual Period:** 90 days

## Payment Practices

- **Payment Terms Changed:** Not available
- **Suppliers Notified of Changes:** Not available
- **E-Invoicing Offered:** True
- **Supply Chain Financing Offered:** False
- **Participates in Payment Codes:** No

## Dispute Resolution

Disputes related to payment are generally resolved informally by discussion between the relevant parties

## Summary

Takeda Development Centre Europe Ltd. is a leading pharmaceutical company with a strong focus on sustainability and innovation. Established in 2004, the company is headquartered in London, UK and is a subsidiary of Takeda Pharmaceutical Company Limited.\n\nThe company's main activities include the development and commercialization of innovative medicines to improve the health and wellbeing of people around the world. Takeda Development Centre Europe Ltd. is committed to sustainability and has implemented various initiatives to reduce their environmental impact, such as reducing waste and investing in renewable energy sources. They also prioritize ethical business practices and have a strict code of conduct in place.\n\nTakeda Development Centre Europe Ltd. has a diverse portfolio of products and services, ranging from prescription drugs to consumer healthcare products. They focus on therapeutic areas such as oncology, gastroenterology, neuroscience, and rare diseases. The company's mission is to provide patients with innovative, safe, and effective treatments that improve their quality of life.\n\nThe key people at Takeda Development Centre Europe Ltd. include Christophe Weber, the President and CEO of Takeda Pharmaceutical Company Limited, and Giles Platford, the President of Takeda Europe and Canada. They lead a team of experienced professionals who are dedicated to advancing the company's mission and values.\n\nFor more information on the company's products, services, and sustainability efforts, visit their website at www.takeda.com. Their registered office address is 1-2 Kingdom Street, London, W2 6BD, United Kingdom. Takeda Development Centre Europe Ltd. continues to be a leader in the pharmaceutical industry, committed to making a positive impact on both patients and the environment.

---

*Data sourced from official UK government payment practices reports. Last updated: 2019-10-03*